Evidence map›Paper›PMID 39937010›Full record

ArticleCells2025

Antimicrobial Blue Light Reduces Human-Wound Pathogens' Resistance to Tetracycline-Class Antibiotics in Biofilms.

Laisa Bonafim Negri, Sandeep Korupolu, William Farinelli, Alexis K Jolly, Robert W Redmond, Shifu Aggarwal, Laurence G Rahme, Kristin H Gilchrist, R Rox Anderson, Jeffrey A Gelfand

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Beta-lactam antibiotics under light: optical and photochemical characterization.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laisa Bonafim NegriWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Boston, MA 02114, USA.
Sandeep KorupoluWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Boston, MA 02114, USA.ORCID 0009-0004-7650-9396
William FarinelliWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Boston, MA 02114, USA.
Alexis K JollySchool of Medicine, University of Edinburgh, Edinburgh EH16 4UX, UK.
Robert W RedmondWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Boston, MA 02114, USA.ORCID 0000-0001-8194-430X
Shifu AggarwalDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
Laurence G RahmeDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
Kristin H Gilchrist4D Bio3 Center for Biotechnology, Department of Radiology and Bioengineering, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA.ORCID 0000-0003-3584-9832
R Rox AndersonWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Boston, MA 02114, USA.
Jeffrey A GelfandWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Boston, MA 02114, USA.ORCID 0000-0002-4118-5676

Funding

Harvard Clinical and Translational Science CenterUM1TR004408 · NCATS · HARVARD MEDICAL SCHOOL · PI Lindsey Robert Baden, Lee Marshall Nadler · 2023 to 2026
$43.3M
NCATS NIH HHS UM1 TR004408United States Department of Defense HU00012420044 and HU00011920056
6 · The paper itself

Abstract

Biofilms contribute to chronic infections and the development of antimicrobial resistance (AMR). We are developing an antimicrobial blue light (aBL) device to reduce bacterial bioburden in wounds and decrease reliance on systemic antibiotics. aBL induces the generation of reactive oxygen species (ROS) through photoexcitation of endogenous chromophores, causing bacterial damage and death. This study explores the combination of tetracyclines (TCs) with aBL for the treatment of biofilm infections in vitro. Tetracyclines (TCs), including second-generation minocycline (MC), doxycycline (DOCT), and third-generation agents omadacycline (OM) and tigecycline (TG), were evaluated for their ability to enhance bactericidal effects and ROS production during aBL treatment of abiotic biofilm. TCs were tested under dark conditions and with varying aBL light parameters against biofilms of methicillin-resistant

Indexed as

Anti-Bacterial AgentsBiofilmsDrug Resistance, BacterialLightTetracyclinesBlue LightEscherichia coliHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsPseudomonas aeruginosaReactive Oxygen SpeciesAnti-Bacterial AgentsReactive Oxygen SpeciesTetracyclinesantimicrobial blue lightantimicrobial resistancebiofilmsphototherapytetracyclineswound infection

Identifiers

PMID39937010
PMCPMC11817061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.